Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans

Trial Profile

Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Teduglutide (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Acronyms GLP-2 Plasma
  • Most Recent Events

    • 19 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 19 Oct 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
    • 19 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top